Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lead Pb 212-DOTAM-GRPR1

A radioconjugate consisting of a gastrin-releasing peptide receptor (GRPR)-targeting antagonist conjugated, through a bifunctional, macrocyclic chelating agent DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide; TCMC), to the alpha-emitting radioisotope lead Pb 212, with potential antineoplastic activity. Upon administration, lead Pb 212-DOTAM-GRPR1 targets and binds to GRPR-expressing tumor cells. This allows for the specific delivery of a cytotoxic dose of alpha radiation to GRPR-expressing tumor cells. GRPR, also called bombesin receptor 2 (BB2), is a G protein-coupled seven-transmembrane receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:212Pb-DOTAM-GRPR1
Pb212-DOTAM-GRPR1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search